How have MRNA shares performed this year?

Moderna's stock was trading at $99.45 at the beginning of 2024. Since then, MRNA stock has increased by 22.8% and is now trading at $122.11. View the best growth stocks for 2024 here .

How were Moderna's earnings last quarter?

Moderna, Inc. (NASDAQ:MRNA) posted its earnings results on Thursday, May, 2nd. The company reported ($3.07) EPS for the quarter, topping analysts' consensus estimates of ($3.59) by $0.52. Moderna's quarterly revenue was down 91.0% on a year-over-year basis.

What is Stéphane Bancel's approval rating as Moderna's CEO?

57 employees have rated Moderna Chief Executive Officer Stéphane Bancel on Glassdoor.com . Stéphane Bancel has an approval rating of 92% among the company's employees. This puts Stéphane Bancel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

When did Moderna IPO?

Moderna (MRNA) raised $499 million in an IPO on Friday, December 7th 2018. The company issued 21,700,000 shares at $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.

Who are Moderna's major shareholders?

Top institutional investors of Moderna include Baillie Gifford & Co. (11.34%), Bank of New York Mellon Corp (0.59%), Sumitomo Mitsui Trust Holdings Inc. (0.38%) and ARK Investment Management LLC (0.28%). Insiders that own company stock include Stephane Bancel , Noubar Afeyan , Stephen Hoge , Shannon Thyme Klinger , Juan Andres , James M Mock , Arpa Garay , David W Meline and Paul Sagan . View institutional ownership trends .

How do I buy shares of Moderna?

Shares of MRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

What other stocks do shareholders of Moderna own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Moderna investors own include NVIDIA (NVDA) , Tesla (TSLA) , Advanced Micro Devices (AMD) , Pfizer (PFE) , Gilead Sciences (GILD) , Inovio Pharmaceuticals (INO) and Novavax (NVAX) .

NASDAQ:MRNA

Moderna (MRNA) Stock Price, News & Analysis

$122.11

+1.71 (+1.42%)

(As of 07/26/2024 ET)

Compare

Today's Range: $119.43
▼
$122.34
50-Day Range: $115.95
▼
$166.61
52-Week Range: $62.55
▼
$170.47

Volume: 1.88 million shs
Average Volume: 4.02 million shs
Market Capitalization: $46.80 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $133.88

Get Moderna alerts:

Moderna MarketRank™ Stock Analysis

Analyst Rating: Hold
2.28 Rating Score
Upside/Downside: 9.6% Upside
$133.88 Price Target
Short Interest: Bearish
6.75% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.71
Upright™ Environmental Score
News Sentiment: 0.41
Based on 27 Articles This Week
Insider Trading: Selling Shares
$53.66 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($7.46) to ($5.29) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.24 out of 5 stars

Medical Sector

226th out of 936 stocks

Biological Products, Except Diagnostic Industry

29th out of 154 stocks

2.1

Analyst's Opinion

Consensus Rating
Moderna has received a consensus rating of Hold. The company's average rating score is 2.28, and is based on 7 buy ratings, 9 hold ratings, and 2 sell ratings.
Amount of Analyst Coverage
Moderna has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.
Read more about Moderna's stock forecast and price target.

1.0

Short Interest

Percentage of Shares Shorted
6.75% of the float of Moderna has been sold short.
Short Interest Ratio / Days to Cover
Moderna has a short interest ratio ("days to cover") of 5.8.
Change versus previous month
Short interest in Moderna has recently increased by 2.76%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Moderna does not currently pay a dividend.
Dividend Growth
Moderna does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Moderna has received a 72.82% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Covid-19 vaccines", "mRNA vaccines", and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Moderna is -2.71.

1.9

News and Social Media Coverage

News Sentiment
Moderna has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 27 news articles for Moderna this week, compared to 19 articles on an average week.
Search Interest
Only 37 people have searched for MRNA on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.
MarketBeat Follows
Only 19 people have added Moderna to their MarketBeat watchlist in the last 30 days. This is a decrease of -21% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Moderna insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $53,661,337.00 in company stock.
Percentage Held by Insiders
15.70% of the stock of Moderna is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
75.33% of the stock of Moderna is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Read more about Moderna's insider trading history.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Moderna are expected to grow in the coming year, from ($7.46) to ($5.29) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Moderna is -7.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Moderna is -7.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Moderna has a P/B Ratio of 3.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
Read more about Moderna's valuation and earnings.

See Top Rated MarketRank™ Stocks Here

Ad Unstoppable Prosperity

“Generational Bull Run” Incoming

LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.

You can find out what they are by clicking here now.

About Moderna Stock (NASDAQ:MRNA)

Moderna Inc., founded in 2010, is a biotechnology company focused on creating transformative medicines to combat viruses and other diseases. The company utilizes messenger ribonucleic acid (mRNA) technology, which transports information from a living creature's DNA to other parts of the body. The company has experienced rapid growth due to its innovative mRNA technologies, especially as the U.S. authorized the COVID-19 vaccine developed by Moderna Inc. for human use in December 2020.

Moderna Inc. operates in multiple therapeutic areas, including infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases. Its product pipeline includes prophylactic vaccines, localized regenerative therapeutics, cancer vaccines, systemic secreted therapeutics, intratumoral immuno-oncology and systemic intracellular therapeutics. The company is also developing vaccines and therapeutics for other infectious diseases, such as influenza, hMPV+PIV3, respiratory syncytial virus, endemic HCoV, cytomegalovirus, human immunodeficiency virus, herpes simplex virus, Epstein-Barr virus and varicella-zoster virus.

Moderna Inc. is actively working to develop a range of pharmaceutical solutions and vaccines and to increase its strategic alliances. The company has seen success in its innovative mRNA technologies, and its growing partnerships have given them an edge over its competitors.

As the company continues to advance its technologies and expand its strategic alliances, Moderna Inc. is proving to be a reliable source of transformative medicines to combat viruses and other diseases.

Moderna Inc. has formed strategic partnerships with a variety of pharmaceutical companies, including AstraZeneca PLC, Merck & Co. Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics Inc., Metagenomi Inc., the Defense Advanced Research Projects Agency, Biomedical Advanced Research and Development Authority, Institute for Life Changing Medicines and the Bill & Melinda Gates Foundation. Furthermore, the company has a collaboration and license agreement with Chiesi Farmaceutici S.P.A.

Written by Jeffrey Neal Johnson

MRNA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MRNA Stock News Headlines

July 21, 2024 | insidertrades.com

Noubar Afeyan Sells 15,000 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock

July 20, 2024 | insidertrades.com

Moderna, Inc. (NASDAQ:MRNA) Director Noubar Afeyan Sells 15,000 Shares

July 26, 2024 | Unstoppable Prosperity (Ad)

“Generational Bull Run” Incoming

LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.

July 17, 2024 | insidertrades.com

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge Sells 15,000 Shares

July 13, 2024 | insidertrades.com

Moderna, Inc. (NASDAQ:MRNA) Director Sells $1,756,200.00 in Stock

July 10, 2024 | insidertrades.com

Moderna, Inc. (NASDAQ:MRNA) CFO James M. Mock Sells 689 Shares

A patient is given a flu vaccine October 28, 2022, in Lynwood, Calif

July 2, 2024 | marketbeat.com

The US will pay Moderna $176 million to develop an mRNA pandemic flu vaccine

The U.S. government will pay the vaccine maker Moderna $176 million to develop a pandemic vaccine that could be used to treat bird flu in people as cases in dairy cows continue to mount across the country

July 2, 2024 | marketbeat.com

US will pay vaccine maker Moderna $176 million to develop an mRNA-based pandemic flu vaccine

July 26, 2024 | Unstoppable Prosperity (Ad)

“Generational Bull Run” Incoming

LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.

June 29, 2024 | insidertrades.com

Moderna, Inc. (NASDAQ:MRNA) Director Sells $1,908,300.00 in Stock

July 26 at 10:37 AM | globenewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA

July 26 at 9:37 AM | finance.yahoo.com

Moderna Insiders Sell US$3.3m Of Stock, Possibly Signalling Caution

July 25 at 8:51 PM | marketwatch.com

Moderna Inc. stock underperforms Thursday when compared to competitors despite daily gains

July 25 at 2:32 AM | americanbankingnews.com

Moderna (MRNA) to Release Earnings on Thursday

July 24 at 8:00 PM | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. - MRNA

July 23 at 6:35 PM | bizjournals.com

Bob Langer, who helped develop mRNA, steps down from Moderna’s board

July 23 at 6:35 PM | marketwatch.com

Moderna Inc. stock outperforms competitors despite losses on the day

July 23 at 8:17 AM | reuters.com

Moderna co-founder Robert Langer to step down from vaccine maker's board

See More Headlines

Receive MRNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Moderna and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/02/2024
Today: 7/26/2024
Next Earnings (Confirmed): 8/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: Pharmaceutical Products
Current Symbol: NASDAQ:MRNA
CUSIP: N/A
CIK: 1682852
Web: www.modernatx.com
Phone: (617) 714-6500
Fax: N/A
Employees: 5,600
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $133.88
High Stock Price Target: $231.00
Low Stock Price Target: $60.00
Potential Upside/Downside: +10.2%
Consensus Rating: Hold
Rating Score (0-4): 2.28
Research Coverage: 18 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($15.67)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-4,714,000,000.00
Net Margins: -115.82%
Pretax Margin: -93.19%
Return on Equity: -20.10%
Return on Assets: -15.00%

Debt

Debt-to-Equity Ratio: 0.04
Current Ratio: 4.03
Quick Ratio: 3.91

Sales & Book Value

Annual Sales: $6.85 billion
Price / Sales: 6.80
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $36.33 per share
Price / Book: 3.35

Miscellaneous

Outstanding Shares: 383,240,000
Free Float: 323,071,000
Market Cap: $46.58 billion
Optionable: Optionable
Beta: 1.66

Social Links

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

Key Executives

Mr. Stephane Bancel (Age 51)
CEO & Director
Comp: $4.55M
Dr. Stephen Hoge M.D. (Age 47)
President
Comp: $1.92M
Mr. James M. Mock (Age 47)
Chief Financial Officer
Comp: $1.4M
Ms. Shannon Thyme Klinger (Age 53)
Chief Legal Officer & Corporate Secretary
Comp: $1.39M
Dr. Jerh Collins Ph.D. (Age 57)
Chief Technical Operations & Quality Officer
Mr. Brad Miller (Age 50)
Chief Information Officer
Ms. Lavina Talukdar CFA
Senior VP & Head of Investor Relations
Colleen Hussey
Senior Director of Corporate Communications
Ms. Tracey Franklin (Age 43)
Chief Human Resources Officer
Dr. Melanie Ivarsson M.B.A.
Ph.D., Chief Development Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

Should I Buy Moderna Stock? MRNA Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Moderna, Inc.:

Moderna's innovative approach to mRNA therapeutics and vaccines could lead to groundbreaking treatments for various diseases, potentially driving significant revenue growth.
Recent insider trading activity, such as President Stephen Hoge selling shares, may indicate confidence in the company's future prospects.
Moderna's strong financial position with a quick ratio of 3.91 and current ratio of 4.03 suggests stability and ability to meet short-term obligations.
The company's market capitalization of $45.34 billion and consistent revenue generation demonstrate its position as a key player in the biotechnology industry.
Moderna's stock price performance, with a 50-day moving average of $135.08 and a 200-day moving average of $113.25, shows positive momentum and potential for growth.

Cons

Investors should be bearish about investing in Moderna, Inc. for these reasons:

Moderna's negative net margin of 115.82% and negative return on equity of 20.10% indicate financial challenges and potential risks for investors.
The company's quarterly revenue decline of 91.0% year-over-year raises concerns about its ability to sustain growth and profitability.
Moderna's high beta of 1.66 suggests higher volatility compared to the market average, which may lead to increased investment risk.
Analysts' prediction of Moderna posting -7.46 earnings per share for the current year signals potential earnings losses that could impact investor confidence.
The fluctuating stock price of Moderna, with a 52-week low of $62.55 and a 52-week high of $170.47, may pose challenges for investors seeking stability in returns.

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, July 7, 2024. Please send any questions or comments about these Moderna pros and cons to contact@marketbeat.com.

MRNA Stock Analysis - Frequently Asked Questions

How have MRNA shares performed this year?: Moderna's stock was trading at $99.45 at the beginning of 2024. Since then, MRNA stock has increased by 22.8% and is now trading at $122.11.
View the best growth stocks for 2024 here.
How were Moderna's earnings last quarter?: Moderna, Inc. (NASDAQ:MRNA) posted its earnings results on Thursday, May, 2nd. The company reported ($3.07) EPS for the quarter, topping analysts' consensus estimates of ($3.59) by $0.52. Moderna's quarterly revenue was down 91.0% on a year-over-year basis.
What is Stéphane Bancel's approval rating as Moderna's CEO?: 57 employees have rated Moderna Chief Executive Officer Stéphane Bancel on Glassdoor.com. Stéphane Bancel has an approval rating of 92% among the company's employees. This puts Stéphane Bancel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
When did Moderna IPO?: Moderna (MRNA) raised $499 million in an IPO on Friday, December 7th 2018. The company issued 21,700,000 shares at $22.00-$24.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.
Who are Moderna's major shareholders?: Top institutional investors of Moderna include Baillie Gifford & Co. (11.34%), Bank of New York Mellon Corp (0.59%), Sumitomo Mitsui Trust Holdings Inc. (0.38%) and ARK Investment Management LLC (0.28%). Insiders that own company stock include Stephane Bancel, Noubar Afeyan, Stephen Hoge, Shannon Thyme Klinger, Juan Andres, James M Mock, Arpa Garay, David W Meline and Paul Sagan.
View institutional ownership trends.
How do I buy shares of Moderna?: Shares of MRNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
What other stocks do shareholders of Moderna own?: Based on aggregate information from My MarketBeat watchlists, some other companies that Moderna investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Pfizer (PFE), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

This page (NASDAQ:MRNA) was last updated on 7/26/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Moderna (MRNA) Stock Price, News & Analysis

Moderna MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Amount of Analyst Coverage

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Yield

Dividend Growth

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Insider Buying vs. Insider Selling

Percentage Held by Insiders

Percentage Held by Institutions

Earnings and Valuation

Earnings Growth

Price to Earnings Ratio vs. the Market

Price to Earnings Ratio vs. Sector

Price to Book Value per Share Ratio

About Moderna Stock (NASDAQ:MRNA)

MRNA Stock Price History

MRNA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

Should I Buy Moderna Stock? MRNA Pros and Cons Explained

Pros

Cons

MRNA Stock Analysis - Frequently Asked Questions

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Overall MarketRank^™